scholarly journals Preferences for Prenatal Tests for Cystic Fibrosis: A Discrete Choice Experiment to Compare the Views of Adult Patients, Carriers of Cystic Fibrosis and Health Professionals

2014 ◽  
Vol 3 (1) ◽  
pp. 176-190 ◽  
Author(s):  
Melissa Hill ◽  
Ranjan Suri ◽  
Edward Nash ◽  
Stephen Morris ◽  
Lyn Chitty
2021 ◽  
Vol 20 ◽  
pp. S109-S110
Author(s):  
R. Cameron ◽  
D. Office ◽  
J. Matthews ◽  
M. Rowley ◽  
J. Abbott ◽  
...  

2019 ◽  
Vol 27 (11) ◽  
pp. 1639-1648 ◽  
Author(s):  
James Buchanan ◽  
Edward Blair ◽  
Kate L. Thomson ◽  
Elizabeth Ormondroyd ◽  
Hugh Watkins ◽  
...  

BMJ Open ◽  
2019 ◽  
Vol 9 (8) ◽  
pp. e030348
Author(s):  
Charlie McLeod ◽  
Richard Norman ◽  
Andre Schultz ◽  
Steven Mascaro ◽  
Steve Webb ◽  
...  

IntroductionClinical decision-making is a complex process. Patient preference information regarding desirable health states should inform treatment and is critical to agreeing on goals of therapy. Cystic fibrosis (CF) is a common, inheritable multisystem disorder for which the major manifestation is progressive, chronic lung disease. Intermittent pulmonary exacerbations are a hallmark of disease and these drive lung damage that results in premature death. We suspect that clinicians make assumptions, most likely implicit assumptions, about outcomes that are desired by patients who are treated for pulmonary exacerbations. The aim of this study is to identify and quantify the preferences of patients with cystic fibrosis regarding treatment outcomes.Methods and analysisWe will develop a discrete choice experiment (DCE) in collaboration with people with CF and their carers, and evaluate how patients make trade-offs between different aspects of health-related status when considering treatment options.Ethics and disseminationEthics approval for all aspects of this study was granted by the Western Australia Child and Adolescent Health Service Human Research Ethics Committee [RGS903]. Weighted preference information from the DCE will be used to develop a multiattribute utility instrument as a measure of treatment success in the upcoming Bayesian Evidence-Adaptive Trial to optimise management of CF. Dissemination of results will also occur through peer-reviewed publications and presentations to relevant stakeholders and research networks.


BMJ Open ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. e045803
Author(s):  
Rebecca Anne Dobra ◽  
Marco Boeri ◽  
Stuart Elborn ◽  
Frank Kee ◽  
Susan Madge ◽  
...  

IntroductionEngaging people with cystic fibrosis (CF) in clinical trials is critical to improving outcomes for this fatal disease. Following extensive exploration of engagement in CF trials we believe six key concepts require a quantitative understanding of their influence in the current CF trials landscape including how controversial issues like placebos, washouts, stipend provision and location of trial visits are viewed by the CF community and how these might be modified depending on the type of medicine being investigated and the mechanism of access to the drug on trial completion.Methods and analysisWe have designed and will administer an online discrete choice experiment to elicit and quantify preferences of people with CF for these trials’ attributes and estimate the relative importance of an attribute when choosing to participate in a trial. The cross-sectional data generated will be explored using conditional multinomial logit model. Mixed logit models such as the random-parameters logit and a latent class models will be used to explore preference heterogeneity. To determine the relative importance of an attribute, the difference between the attribute level with the highest preference weight and the level with the lowest preference weight will be calculated.Ethics and disseminationImperial College London Joint Research Compliance Office has granted ethical approval for this study. Patient consent will be sought following full explanation. No identifying information will be collected. Dissemination will be via international conferences, peer-review publication and patient accessible forums. Major CF trials networks have agreed to incorporate our findings into their review process, meaning our results can realistically influence and optimise CF trial delivery.PROSPERO registration numberCRD42020184886.


2012 ◽  
Vol 12 (1) ◽  
Author(s):  
Peter C Rockers ◽  
Wanda Jaskiewicz ◽  
Laura Wurts ◽  
Margaret E Kruk ◽  
George S Mgomella ◽  
...  

2019 ◽  
Vol 111 (7) ◽  
pp. 1243-1260 ◽  
Author(s):  
Alex Roach ◽  
Bruce K. Christensen ◽  
Elizabeth Rieger

2019 ◽  
Author(s):  
Y Peters ◽  
E van Grinsven ◽  
M van de Haterd ◽  
D van Lankveld ◽  
J Verbakel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document